Pharm'Up 
A major milestone in industrial biotechnology has been reached as scientists have developed an engineered bacterial strain that produces unprecedented amounts of monensin, a key antibiotic utilized in veterinary care and agriculture. This groundbreaking research, detailed in the journal Bioengineered, stems from an in-depth genomic study of Streptomyces cinnamonensis, a soil bacterium naturally capable of generating monensin.
Through meticulous genome analysis, researchers pinpointed specific genes critical to core metabolic functions, particularly those linked to fatty acid breakdown and the generation of energy-rich molecules essential for antibiotic synthesis. Four genes—fadD, fadE, fadB, and fadA—emerged as prime candidates. Overexpressing each gene individually in the bacterium increased monensin production by up to 22%.
Leveraging this knowledge, the team created an enhanced strain called “M5,” which simultaneously overexpressed all four genes. The outcome was remarkable: the M5 strain yielded nearly 19 grams per liter of monensin in shake-flask fermentation, a 30% improvement over the original strain. In larger 50-liter bioreactor experiments, production soared to 37.3 grams per liter, setting a new global record for monensin output.
The breakthrough hinges on optimizing the bacterium’s metabolic pathways. The modified strain directs more energy and resources toward monensin production by boosting levels of malonyl-CoA, a vital component for many antibiotics. Additionally, the process became more efficient with a 33% decrease in fatty acid waste.
This achievement not only establishes a new benchmark for monensin production but also demonstrates a versatile method for enhancing the yield of valuable compounds in microbial systems. By integrating genome mining with precise metabolic engineering, the study paves the way for sustainable, cost-effective production of antibiotics and other significant bioactive substances.
About the Author
